$14.70
0.27% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Target price 2025 - Analyst rating & recommendation

Roivant Sciences Classifications & Recommendation:

Buy
88%
Hold
12%

Roivant Sciences Price Target

Target Price $18.36
Price $14.70
Potential
Number of Estimates 12
12 Analysts have issued a price target Roivant Sciences 2026 . The average Roivant Sciences target price is $18.36. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 15 Analysts recommend Roivant Sciences to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2026 of . Most analysts recommend the Roivant Sciences stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Million $ 29.05 24.93
11.19% 14.20%
EBITDA Margin -3,785.23% -5,171.88%
54.21% 36.63%
Net Margin -592.01% -3,948.52%
104.45% 566.96%

12 Analysts have issued a sales forecast Roivant Sciences 2026 . The average Roivant Sciences sales estimate is

$24.9m
Unlock
. This is
7.30% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$49.6m 113.34%
Unlock
, the lowest is
$9.1m 60.82%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $29.1m 11.19%
2026
$24.9m 14.20%
Unlock
2027
$86.8m 248.22%
Unlock
2028
$570m 556.44%
Unlock
2029
$1.4b 150.11%
Unlock
2030
$2.4b 69.33%
Unlock
2031
$3.5b 44.63%
Unlock
2032
$4.8b 36.70%
Unlock

5 Analysts have issued an Roivant Sciences EBITDA forecast 2026. The average Roivant Sciences EBITDA estimate is

$-1.3b
Unlock
. This is
9.64% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-1.2b 2.88%
Unlock
, the lowest is
$-1.4b 21.36%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-1.1b 36.96%
2026
$-1.3b 17.23%
Unlock
2027
$-915m 28.99%
Unlock
2028
$-756m 17.37%
Unlock

EBITDA Margin

2025 -3,785.23% 54.21%
2026
-5,171.88% 36.63%
Unlock
2027
-1,054.69% 79.61%
Unlock
2028
-132.77% 87.41%
Unlock

12 Roivant Sciences Analysts have issued a net profit forecast 2026. The average Roivant Sciences net profit estimate is

$-984m
Unlock
. This is
100.59% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-845m 72.28%
Unlock
, the lowest is
$-1.4b 180.72%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-172m 103.95%
2026
$-984m 472.26%
Unlock
2027
$-974m 1.08%
Unlock
2028
$-543m 44.25%
Unlock
2029
$-48.7m 91.03%
Unlock
2030
$386m 892.88%
Unlock
2031
$894m 131.53%
Unlock
2032
$1.8b 99.22%
Unlock

Net Margin

2025 -592.01% 104.45%
2026
-3,948.52% 566.96%
Unlock
2027
-1,121.67% 71.59%
Unlock
2028
-95.27% 91.51%
Unlock
2029
-3.42% 96.41%
Unlock
2030
16.01% 568.13%
Unlock
2031
25.62% 60.02%
Unlock
2032
37.34% 45.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share $ -0.23 -1.44
104.40% 526.09%
P/E negative
EV/Sales 222.07

12 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences EPS is

$-1.44
Unlock
. This is
100.00% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.24 72.22%
Unlock
, the lowest is
$-2.02 180.56%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.23 104.40%
2026
$-1.44 526.09%
Unlock
2027
$-1.43 0.69%
Unlock
2028
$-0.80 44.06%
Unlock
2029
$-0.07 91.25%
Unlock
2030
$0.57 914.29%
Unlock
2031
$1.31 129.82%
Unlock
2032
$2.61 99.24%
Unlock

P/E ratio

Current -20.42 1,196.73%
2026
-10.19 50.09%
Unlock
2027
-10.30 1.08%
Unlock
2028
-18.48 79.42%
Unlock
2029
-205.88 1,014.07%
Unlock
2030
25.97 112.61%
Unlock
2031
11.22 56.80%
Unlock
2032
5.63 49.82%
Unlock

Based on analysts' sales estimates for 2026, the Roivant Sciences stock is valued at an EV/Sales of

222.07
Unlock
and an P/S ratio of
402.74
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 238.28 657.41%
2026
222.07 6.80%
Unlock
2027
63.77 71.28%
Unlock
2028
9.72 84.77%
Unlock
2029
3.88 60.02%
Unlock
2030
2.29 40.95%
Unlock
2031
1.59 30.86%
Unlock
2032
1.16 26.85%
Unlock

P/S ratio

Current 432.13 442.65%
2026
402.74 6.80%
Unlock
2027
115.66 71.28%
Unlock
2028
17.62 84.77%
Unlock
2029
7.04 60.02%
Unlock
2030
4.16 40.95%
Unlock
2031
2.88 30.86%
Unlock
2032
2.10 26.85%
Unlock

Current Roivant Sciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B of A Securities
Locked
Locked
Locked Sep 18 2025
Leerink Partners
Locked
Locked
Locked Sep 18 2025
JP Morgan
Locked
Locked
Locked Sep 18 2025
Jefferies
Locked
Locked
Locked Sep 18 2025
HC Wainwright & Co.
Locked
Locked
Locked Sep 18 2025
Guggenheim
Locked
Locked
Locked Sep 18 2025
Goldman Sachs
Locked
Locked
Locked Sep 18 2025
Analyst Rating Date
Locked
B of A Securities:
Locked
Locked
Sep 18 2025
Locked
Leerink Partners:
Locked
Locked
Sep 18 2025
Locked
JP Morgan:
Locked
Locked
Sep 18 2025
Locked
Jefferies:
Locked
Locked
Sep 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 18 2025
Locked
Guggenheim:
Locked
Locked
Sep 18 2025
Locked
Goldman Sachs:
Locked
Locked
Sep 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today